Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJamie R. WagnerDYDongyun YangSOSalman Otoukesh

Discussion

Loading...

Member takes

Overview

Trial shows improved safety for CD6-CAR Tregs in cGVHD patients, suggesting a new therapy approach.

Key Points

  • CD6-CAR Tregs achieved high safety without significant toxicity or limiting side effects in patients.
  • Safety measures included monitoring for adverse events during the initial 28-day period post-infusion.
  • Phase I trial with allogeneic CD6-CAR Tregs demonstrated promising results in managing cGVHD symptoms.
  • Early findings highlight the potential of CD6-CAR Tregs in treating chronic graft-versus-host disease effectively.

Cite This Study

Wagner et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de36https://doi.org/10.1182/blood-2025-276
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells2025 · 6 citations
  2. 2Automated GMP-Compatible Production of Universal CAR Tregs for Organ-Targeted Tolerance Induction2025
  3. 3Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies2025 · 1 citations
  4. 4CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study2025
  5. 5In Vivo clonal dynamics of alloreactive CAR T cells reveal mechanisms limiting gvhd risk following allogeneic CAR T cell therapy2025